Previous 10 | Next 10 |
home / stock / orxof / orxof news
FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies Preliminary estimated sales potential of USD 420 -650 million for the DTx portfolio five years post launch To enab...
UPPSALA, Sweden , June 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorpt...
UPPSALA, Sweden , June 17, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substanc...
NEW YORK , June 15, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Global Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited ...
UPPSALA, Sweden , May 19, 2020 /PRNewswire/ -- Today on 19 May 2020 , Orexo AB (publ) held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions. Long-term incentive program LTIP 2020 The extraordinary general meeting resolved, in acco...
UPPSALA, Sweden and NEW YORK , May 18, 2020 /PRNewswire/ -- Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a patient empowerment platform, to work with substance abuse patients to id...
UPPSALA, Sweden , May 15, 2020 /PRNewswire/ -- Orexo's partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammato...
UPPSALA, Sweden , May 11, 2020 /PRNewswire/ -- Orexo AB (publ.) today announces it has acquired the exclusive US rights to GAIA AG's (GAIA) deprexis®, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the...
UPPSALA, Sweden , April 28, 2020 /PRNewswire/ -- Q1 2020 highlights Total net revenues of SEK 175.0 m (174.3), up 0.4 percent EBITDA of SEK 39.1 m (...
UPPSALA, Sweden , April 6, 2020 /PRNewswire/ -- Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020 . A total of 500,000 shares, equivalent to approximately 1.4 per cent of the issued ordinary shares in the compan...
News, Short Squeeze, Breakout and More Instantly...
Orexo Ab Ord Company Name:
ORXOF Stock Symbol:
OTCMKTS Market:
Orexo's patent win for ZUBSOLV® appealed PR Newswire UPPSALA, Sweden , July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
Orexo Q4 2020, incl. Full Year Report ZUBSOLV® stable and strong EBIT, despite challenging market due to COVID-19 PR Newswire UPPSALA, Sweden , Jan. 28, 2021 /PRNewswire/ -- Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 la...
Orexo announces new US patent for ZUBSOLV® PR Newswire UPPSALA, Sweden , Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®...